« Return to News | CROs/Service Providers

Clinipace Worldwide acquires Regulus Pharmaceutical Consulting

Tuesday, March 1, 2011 11:56 AM

Clinipace Worldwide, a global digital CRO based in Morrisville, N.C., has acquired Regulus Pharmaceutical Consulting, a regulatory affairs and quality assurance consultancy based in Boulder, Colo.  

With this acquisition, Clinipace has expanded its regulatory and strategic development expertise and increased its staff by 20%. The Regulus team will remain in Colorado with the same management structure and personnel and will operate as the regulatory affairs, strategic development and quality assurance consultancy division of Clinipace.  

Brenda Fielding, Regulus president, will become executive vice president of regulatory affairs for Clinipace. Prior to Regulus, she held senior management positions in U.S. pharmaceutical and biotechnology companies, involved in clinical development over a range of therapeutic areas including oncology, anti-infectives, immunotherapeutics and ophthalmology.

With specific expertise in oncology, among other therapeutic areas, Clinipace has managed over 200 contract research and regulatory projects.  Headquartered in Research Triangle Park, N.C., it also has operations in Overland Park, Kan., Boulder, Colo., and South American operations in Brazil, Argentina and Peru.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.